PHAnews is meant to give a picture
of recent events
and activities affecting the life of the PH community.
This compilation should not be viewed as endorsement
of the information provided or its accuracy.
Awareness
Month:
Celebrating 15 Years of the PH Community
Each November, the PH community
celebrates PH Awareness Month. This is a special
time to focus our energy around raising awareness
of PH and support for the PH community. This November,
celebrate 15 years of ending isolation and raising
awareness. Participate in one of the activities
found at www.phassociation.org/
Awareness, or create your own!
Encysive
Pharmaceuticals, Inc. [ENCY] and Pulmonary Hypertension
Association Ring the Opening Bell
Bruce D. Given, M.D., President and
CEO of Encysive Pharmaceuticals, Inc. (NASDAQ: ENCY),
and Rino Aldrighetti, President of Pulmonary Hypertension
Association (PHA) preside over the opening bell to
kick off Pulmonary Hypertension Awareness Month. PHA
also launched its national "Faces of PAH"
public awareness and educational campaign at the Opening.
Pulmonary
Hypertension Association Announces Launch of "Faces of
PAH" National Public Awareness Campaign
Silver Spring, MD - November
2, 2005 - The Pulmonary Hypertension Association (PHA)
today announced the launch of its new national disease
awareness campaign, "Faces of PAH," to draw
attention to a life-threatening blood vessel disorder
of the lung. The initiative's kick off coincides with
PHA ringing the bell at NASDAQ this morning, along with
Encysive Pharmaceuticals, to usher in Pulmonary Hypertension
Awareness Month. The goal of the campaign is to raise
the profile of pulmonary arterial hypertension (PAH),
a rare and often undiagnosed disease which afflicts an
estimated 100,000 to 200,000 people worldwide.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information
resource for people dealing with PH -- they have ARRIVED
and are ready to ship!!!
The author, a PH patient
herself, knows what it is like to live with the disease.
She talked to many other patients, doctors, and researchers
while writing the Survival Guide. Dr. Ronald J. Oudiz
and a team of physicians with a deep knowledge of
PH edited the book for accuracy.
New edition contains
a chart of 15 drugs used to treat
PH; results of recent clinical trials;
in-depth discussion of PH secondary to other
diseases or conditions; a new chapter on
what to eat if you have PH; and much,
much more!
Fewer
Liver Function Abnormalities Seen with Sitaxsetan in Pulmonary
Hypertension: Presented at CHEST
MONTREAL, CANADA
-- November 2, 2005 -- Significantly fewer patients with
pulmonary arterial hypertension experienced abnormal liver
function tests while on the investigational endothelin receptor
antagonist sitaxsetan than while on bosentan, researchers
reported here at CHEST 2005, the American College of Chest
Physicians annual meeting.
CoTherix to Initiate Clinical Registry to Study Pulmonary Arterial Hypertension
SOUTH SAN FRANCISCO, Calif., Oct. 24 /PRNewswire-FirstCall/ -- CoTherix,
Inc. (Nasdaq: CTRX) announced today its plans to initiate a first-of-its-kind
national disease registry that will retrospectively and prospectively collect
observational data to track and study the natural history and medical
management of pulmonary arterial hypertension (PAH), World Health Organization
Group I. PAH is a chronic, progressive and often fatal disease characterized
by severe constriction of the blood vessels in the lungs.
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
